PEER CONNECTION

Original iovera° conversations as lead by thought leaders in your industry.

Real-World Business and Safety Solutions with iovera°: January 2021 Newsletter

Introduction to the Smart Tip 190 under ultrasound and differentiation of iovera° from comparative technologies. Features exclusive interview content from Dr Pieter Vreede, Anesthesiologist, and Chad Miller, CRNA.

Key Factors in Migration of Total Knee Arthroplasty to Outpatient Settings

Article written by Stan Dysart, MD, MBA and Nirav Amin, MD. Published as an advertising feature for the Eastern Orthopaedic Association (EOA) in the Journal of Surgical Orthopaedic Advances. September 14, 2020

Real-World Pain Strategy Solutions with iovera°: August 2020 Newsletter

Technology and clinical data overview. Features exclusive interview content from Dr Scott Sigman and his NP Kristen Proverb, and Dr Robert Limoni and his PA Todd Bruss.

Speaker: Cryoanalgesia as a Part of a Multimodal Solution to Manage TKA Pain

 

Virtual event that reviews the history of cryoanalgesia devices, introduces the technology behind iovera°, and discusses the core clinical data supporting the safety, efficacy, and efficiency of iovera°. Dr Dasa also addresses the climate revolving around health care during COVID-19 pandemic. Presented by Vinod Dasa, MD
4/1/2020

CONTACT US

You can find additional resources, podcasts, and more at the Pacira Innovation Hub

Pacira Innovation Hub
Return to the Resource Center

IndicationThe iovera° system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days. The iovera° system is not indicated for treatment of central nervous system tissue. The iovera° system’s “1x90” Smart Tip configuration (indicating one needle which is 90 mm long) can also facilitate target nerve location by conducting electrical nerve stimulation from a separate nerve stimulator.

Important Safety Information

ContraindicationsThe iovera° system is contraindicated for use in patients with the following:

  • Cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud’s disease, and open and/or infected wounds at or near the treatment site

Potential ComplicationsAs with any surgical treatment that uses needle-based therapy and local anesthesia, there is a potential for site-specific reactions, including, but not limited to:

  • Ecchymosis, edema, erythema, local pain and/or tenderness, and localized dysesthesia

Proper use of the device as described in the User Guide can help reduce or prevent the following complications :

  • At the treatment site(s): injury to the skin related to application of cold or heat, hyper- or hypopigmentation, and skin dimpling
  • Outside the treatment site(s): loss of motor function
SEE MORE

The iovera° system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain.

Important Safety Information